Cost-Effectiveness Analysis Comparing Conventional Versus Stereotactic Body Radiotherapy for Surgically Ineligible Stage I Non–Small-Cell Lung Cancer - Concepedia

Concepedia

Publication | Closed Access

Cost-Effectiveness Analysis Comparing Conventional Versus Stereotactic Body Radiotherapy for Surgically Ineligible Stage I Non–Small-Cell Lung Cancer

46

Citations

17

References

2014

Year

Gunita Mitera, Anand Swaminath, David Rudoler, Colleen Seereeram, Meredith Giuliani, Natasha B. Leighl, Eric Gutierrez, Mark Dobrow, Peter C. Coyte, Terence Yung,

Journal of Oncology Practice

Abstract

The authors show that based on a threshold of $50,000 per life-year gained, stereotactic body radiotherapy seems cost effective compared with conventionally fractionated radiotherapy.

References

	Year	Citations

Page 1